ESMO26: Intismeran sets new benchmark in adjuvant melanoma
One notable finding from the INTerpath-001 trial, for which data was presented at ESMO 2026, was when the benefit appeared.
One notable finding from the INTerpath-001 trial, for which data was presented at ESMO 2026, was when the benefit appeared.